Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 588

1.

Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma.

Giridhar KV, Sosa CP, Hillman DW, Sanhueza C, Dalpiaz CL, Costello BA, Quevedo FJ, Pitot HC, Dronca RS, Ertz D, Cheville JC, Donkena KV, Kohli M.

Int J Mol Sci. 2017 Nov 3;18(11). pii: E2326. doi: 10.3390/ijms18112326.

2.

A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.

Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M.

Ann Oncol. 2018 Feb 1;29(2):352-360. doi: 10.1093/annonc/mdx689.

PMID:
29069303
3.

Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.

Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM.

Clin Cancer Res. 2017 Aug 15;23(16):4704-4715. doi: 10.1158/1078-0432.CCR-17-0017. Epub 2017 May 4.

PMID:
28473535
4.

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.

Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N.

Oncotarget. 2017 May 23;8(21):35326-35338. doi: 10.18632/oncotarget.15108.

5.

Role of Ultraviolet Radiation in Papillomavirus-Induced Disease.

Uberoi A, Yoshida S, Frazer IH, Pitot HC, Lambert PF.

PLoS Pathog. 2016 May 31;12(5):e1005664. doi: 10.1371/journal.ppat.1005664. eCollection 2016 May.

6.
7.

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.

Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N.

J Natl Cancer Inst. 2015 Sep 14;107(11). pii: djv248. doi: 10.1093/jnci/djv248. Print 2015 Nov. Erratum in: J Natl Cancer Inst. 2016 Apr;108(4). pii: djw057. doi: 10.1093/jnci/djw057.

8.

Ureteral obstruction in cancer patients: a qualitative study.

Kumar A, Mynderse L, Patel K, Grudem M, Bakkum-Gamez J, Longenbach S, Block MS, Pitot HC, Garovic V, Weroha SJ, Jatoi A.

Psychooncology. 2016 May;25(5):605-9. doi: 10.1002/pon.3889. Epub 2015 Jun 22. No abstract available.

PMID:
26101949
9.

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study.

Hurwitz HI, Smith DC, Pitot HC, Brill JM, Chugh R, Rouits E, Rubin J, Strickler J, Vuagniaux G, Sorensen JM, Zanna C.

Cancer Chemother Pharmacol. 2015 Apr;75(4):851-9. doi: 10.1007/s00280-015-2709-8. Epub 2015 Feb 27.

10.

Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.

O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N.

J Clin Oncol. 2014 Jun 20;32(18):1927-34. doi: 10.1200/JCO.2013.53.7753. Epub 2014 May 5.

11.

Liver tumor promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin is dependent on the aryl hydrocarbon receptor and TNF/IL-1 receptors.

Kennedy GD, Nukaya M, Moran SM, Glover E, Weinberg S, Balbo S, Hecht SS, Pitot HC, Drinkwater NR, Bradfield CA.

Toxicol Sci. 2014 Jul;140(1):135-43. doi: 10.1093/toxsci/kfu065. Epub 2014 Apr 9.

12.

High incidence of HPV-associated head and neck cancers in FA deficient mice is associated with E7's induction of DNA damage through its inactivation of pocket proteins.

Park JW, Shin MK, Pitot HC, Lambert PF.

PLoS One. 2013 Sep 23;8(9):e75056. doi: 10.1371/journal.pone.0075056. eCollection 2013.

13.

Cervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoprotein.

Jabbar SF, Park S, Schweizer J, Berard-Bergery M, Pitot HC, Lee D, Lambert PF.

Cancer Res. 2012 Aug 15;72(16):4008-16. doi: 10.1158/0008-5472.CAN-11-3085. Epub 2012 Jun 13.

14.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM.

N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.

15.

Pocket proteins suppress head and neck cancer.

Shin MK, Pitot HC, Lambert PF.

Cancer Res. 2012 Mar 1;72(5):1280-9. doi: 10.1158/0008-5472.CAN-11-2833. Epub 2012 Jan 11.

16.

On the passing of Gerald C. Mueller, MD, PhD (1920–2010).

Boutwell RK, Burgess RR, Dove W, Pitot HC.

Cancer Res. 2011 Nov 1;71(21):6909-10. No abstract available.

17.

Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ.

J Clin Oncol. 2012 Jan 20;30(3):263-7. doi: 10.1200/JCO.2011.37.1039. Epub 2011 Dec 12.

18.

Dominant role of HPV16 E7 in anal carcinogenesis.

Thomas MK, Pitot HC, Liem A, Lambert PF.

Virology. 2011 Dec 20;421(2):114-8. doi: 10.1016/j.virol.2011.09.018. Epub 2011 Oct 13.

19.

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C.

Cancer. 2012 May 1;118(9):2424-30. doi: 10.1002/cncr.26556. Epub 2011 Sep 27.

20.

Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials.

An MW, Mandrekar SJ, Branda ME, Hillman SL, Adjei AA, Pitot HC, Goldberg RM, Sargent DJ.

Clin Cancer Res. 2011 Oct 15;17(20):6592-9. doi: 10.1158/1078-0432.CCR-11-0822. Epub 2011 Aug 31.

21.

Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741.

Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS.

J Clin Oncol. 2011 Apr 20;29(12):1599-606. doi: 10.1200/JCO.2010.31.7255. Epub 2011 Mar 21.

22.

Rapamycin inhibits anal carcinogenesis in two preclinical animal models.

Stelzer MK, Pitot HC, Liem A, Lee D, Kennedy GD, Lambert PF.

Cancer Prev Res (Phila). 2010 Dec;3(12):1542-51. doi: 10.1158/1940-6207.CAPR-10-0228.

23.

A mouse model for human anal cancer.

Stelzer MK, Pitot HC, Liem A, Schweizer J, Mahoney C, Lambert PF.

Cancer Prev Res (Phila). 2010 Dec;3(12):1534-41. doi: 10.1158/1940-6207.CAPR-10-0086. Epub 2010 Oct 6.

24.

Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer.

Park JW, Pitot HC, Strati K, Spardy N, Duensing S, Grompe M, Lambert PF.

Cancer Res. 2010 Dec 1;70(23):9959-68. doi: 10.1158/0008-5472.CAN-10-1291. Epub 2010 Oct 8.

25.

Incidental findings in imaging research: evaluating incidence, benefit, and burden.

Orme NM, Fletcher JG, Siddiki HA, Harmsen WS, O'Byrne MM, Port JD, Tremaine WJ, Pitot HC, McFarland EG, Robinson ME, Koenig BA, King BF, Wolf SM.

Arch Intern Med. 2010 Sep 27;170(17):1525-32. doi: 10.1001/archinternmed.2010.317.

26.

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.

Kim GP, Mahoney MR, Szydlo D, Mok TS, Marshke R, Holen K, Picus J, Boyer M, Pitot HC, Rubin J, Philip PA, Nowak A, Wright JJ, Erlichman C.

Invest New Drugs. 2012 Feb;30(1):387-94. doi: 10.1007/s10637-010-9532-1. Epub 2010 Sep 14.

27.

Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice.

Jabbar S, Strati K, Shin MK, Pitot HC, Lambert PF.

Virology. 2010 Nov 10;407(1):60-7. doi: 10.1016/j.virol.2010.08.003. Epub 2010 Aug 24.

28.

E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice.

Shai A, Pitot HC, Lambert PF.

Cancer Res. 2010 Jun 15;70(12):5064-73. doi: 10.1158/0008-5472.CAN-09-3307. Epub 2010 Jun 8.

29.

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD.

J Clin Oncol. 2010 Jul 20;28(21):3491-7. doi: 10.1200/JCO.2010.28.4075. Epub 2010 Jun 7.

30.

A role for HPV16 E5 in cervical carcinogenesis.

Maufort JP, Shai A, Pitot HC, Lambert PF.

Cancer Res. 2010 Apr 1;70(7):2924-31. doi: 10.1158/0008-5472.CAN-09-3436. Epub 2010 Mar 23.

31.

Long-lived Min mice develop advanced intestinal cancers through a genetically conservative pathway.

Halberg RB, Waggoner J, Rasmussen K, White A, Clipson L, Prunuske AJ, Bacher JW, Sullivan R, Washington MK, Pitot HC, Petrini JH, Albertson DG, Dove WF.

Cancer Res. 2009 Jul 15;69(14):5768-75. doi: 10.1158/0008-5472.CAN-09-0446. Epub 2009 Jul 7.

32.

Disruption of estrogen receptor signaling enhances intestinal neoplasia in Apc(Min/+) mice.

Cleveland AG, Oikarinen SI, Bynoté KK, Marttinen M, Rafter JJ, Gustafsson JA, Roy SK, Pitot HC, Korach KS, Lubahn DB, Mutanen M, Gould KA.

Carcinogenesis. 2009 Sep;30(9):1581-90. doi: 10.1093/carcin/bgp132. Epub 2009 Jun 11.

33.

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

Kim GP, Sargent DJ, Mahoney MR, Rowland KM Jr, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC.

J Clin Oncol. 2009 Jun 10;27(17):2848-54. doi: 10.1200/JCO.2008.20.4552. Epub 2009 Apr 20.

34.

Predominant modifier of extreme liver cancer susceptibility in C57BR/cdJ female mice localized to 6 Mb on chromosome 17.

Peychal SE, Bilger A, Pitot HC, Drinkwater NR.

Carcinogenesis. 2009 May;30(5):879-85. doi: 10.1093/carcin/bgp054. Epub 2009 Mar 2.

35.

Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741.

Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M.

Clin Cancer Res. 2008 Dec 15;14(24):8263-9. doi: 10.1158/1078-0432.CCR-08-0480. Epub 2008 Dec 10.

36.
37.

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G.

Clin Cancer Res. 2008 Dec 1;14(23):7940-6. doi: 10.1158/1078-0432.CCR-08-0221.

38.

Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.

Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM.

J Clin Oncol. 2008 Dec 10;26(35):5721-7. doi: 10.1200/JCO.2008.17.7147. Epub 2008 Nov 10.

39.

The pleiotropic phenotype of Apc mutations in the mouse: allele specificity and effects of the genetic background.

Halberg RB, Chen X, Amos-Landgraf JM, White A, Rasmussen K, Clipson L, Pasch C, Sullivan R, Pitot HC, Dove WF.

Genetics. 2008 Sep;180(1):601-9. doi: 10.1534/genetics.108.091967. Epub 2008 Aug 24.

40.

p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers.

Shai A, Pitot HC, Lambert PF.

Cancer Res. 2008 Apr 15;68(8):2622-31. doi: 10.1158/0008-5472.CAN-07-5266.

41.

A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.

Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD.

Invest New Drugs. 2008 Aug;26(4):369-79. doi: 10.1007/s10637-008-9123-6. Epub 2008 Feb 16.

42.

Adventures in hepatocarcinogenesis.

Pitot HC.

Annu Rev Pathol. 2007;2:1-29. Review.

PMID:
18039091
43.

CpG PatternFinder: a Windows-based utility program for easy and rapid identification of the CpG methylation status of DNA.

Xu YH, Manoharan HT, Pitot HC.

Biotechniques. 2007 Sep;43(3):334, 336-40, 342.

PMID:
17907576
44.

Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.

Dy GK, Krook JE, Green EM, Sargent DJ, Delaunoit T, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pockaj BA, Sticca RP, Alberts SR, Pitot HC 4th, Goldberg RM; Intergroup N9741.

J Clin Oncol. 2007 Aug 10;25(23):3469-74. Erratum in: J Clin Oncol. 2007 Nov 20;25(33):5339.

PMID:
17687151
45.

Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis.

Maufort JP, Williams SM, Pitot HC, Lambert PF.

Cancer Res. 2007 Jul 1;67(13):6106-12.

46.

Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.

Ashley AC, Sargent DJ, Alberts SR, Grothey A, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM.

Cancer. 2007 Aug 1;110(3):670-7.

47.

A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma.

Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET.

Am J Clin Oncol. 2007 Jun;30(3):303-9.

PMID:
17551310
48.

Hepatocellular carcinomas of the albumin SV40 T-antigen transgenic rat display fetal-like re-expression of lgf2 and deregulation of H19.

Czarny MJ, Babcock K, Baus RM, Manoharan H, Pitot HC.

Mol Carcinog. 2007 Sep;46(9):747-57.

PMID:
17393425
49.

Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model.

Strati K, Pitot HC, Lambert PF.

Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14152-7. Epub 2006 Sep 7.

50.

Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.

Markovic SN, Suman VJ, Ingle JN, Kaur JS, Pitot HC, Loprinzi CL, Rao RD, Creagan ET, Pittelkow MR, Allred JB, Nevala WK, Celis E.

Am J Clin Oncol. 2006 Aug;29(4):352-60.

PMID:
16891861

Supplemental Content

Loading ...
Support Center